Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows
The analysis revealed that patients with prescriptions for GIP or GLP-1 RA drugs, e.g., A recent real-world data analysis was conducted to suggest a link between glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) prescriptions and reduced rates of opioid overdose and alcohol intoxication among patients with opioid use disorder (OUD) and alcohol use disorder (AUD).
最近進行了一項真實世界數據分析，建議葡萄糖依賴性胃腸肽（GIP）和胰高血糖素樣肽-1受體激動劑（GLP-1 RA）的處方與阿片類藥物使用障礙（OUD）和酒精使用障礙（AUD）患者中的阿片類藥物過量和酒精中毒率降低之間存在聯繫。
The study, which included over 500,000 OUD patients and more than 800,000 AUD patients, presents promising insights for novel treatment strategies in substance use disorders.
這項研究納入了50多萬OUD患者和80多萬AUD患者，爲物質使用障礙中的新型治療策略提供了有希望的見解。
Also Read: Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users.
另請閱讀：熱門藥物Ozempic可能有新用途，甲糖肽藥物與糖尿病阿片用戶減少過量風險有關。
The analysis revealed that patients with prescriptions for GIP or GLP-1 RA drugs, e.g., Novo Nordisk A/S' (NYSE:NVO) Ozempic (semaglutide), experienced significantly lower rates of opioid overdose and alcohol intoxication compared to those without such prescriptions.
分析表明，使用GIP或GLP-1 RA藥物處方的患者，如諾和諾德公司（紐交所：NVO）的Ozempic（甲糖肽），與沒有此類處方的患者相比，阿片類藥物過量和酒精中毒率顯著降低。
Specifically, patients with OUD who received GIP/GLP-1 RA prescriptions had a 40% lower rate of opioid overdose, while AUD patients showed a 50% reduction in alcohol intoxication rates.
具體來說，接受GIP/GLP-1 RA處方的OUD患者阿片類藥物過量率降低40％，而AUD患者的酒精中毒率降低50％。
These protective effects remained strong even among subgroups with comorbid conditions like type 2 diabetes and obesity.
即使在患有2型糖尿病和肥胖等並存疾病的亞組中，這種保護效果仍然顯著。
Previous animal studies have demonstrated similar findings with GLP-1 RA drugs, such as Saxenda and Victoza (liraglutide) and semaglutide, reducing alcohol intake and drug-seeking behaviors in rodents.
先前的動物研究證明使用GLP-1 RA藥物，如Saxenda和Victoza（利拉魯肽）和甲糖肽，可以減少齧齒動物的飲酒和尋藥行爲。
Clinical trials in humans are still ongoing, examining the role of these drugs in curbing substance-related behaviors, such as cigarette smoking, opioid cravings, and alcohol use.
人體的臨床試驗仍在進行中，研究這些藥物在抑制與物質相關的行爲，如吸菸、阿片渴望和酒精使用中的作用。
While early trials indicate a reduction in heavy drinking days for AUD patients, further large-scale studies are needed to assess the generalizability of these results.
儘管早期試驗表明對aud患者減少了大量飲酒日，但需要進一步進行大規模研究以評估這些結果的普適性。
The study emphasizes the need for further research, particularly through prospective clinical trials, to confirm the protective associations between GIP/GLP-1 RA drugs and substance use outcomes.
該研究強調了需要進一步研究，特別是通過前瞻性臨床試驗來確認gip/glp-1 ra藥物與物質使用結果之間的保護性關聯。
The findings contribute to the evolving landscape of addiction treatment and could lead to the development of more comprehensive pharmacotherapy options for individuals battling OUD and AUD.
這些發現有助於成癮治療領域的不斷髮展，並可能導致開發更全面的藥物治療選擇，幫助那些與oud和aud作鬥爭的個人。
Price Action: NVO stock is up 0.53% at $118.66 at last check Thursday.
股價走勢：紐交所股票最新報價爲118.66美元，週四最後查詢時上漲了0.53%。
- EXCLUSIVE: Adial Pharmaceuticals Secures Additional US Patent Expanding Intellectual Property Protection Around Its Alcohol Use Disorder Candidate.
- 獨家報道：adial pharmaceuticals獲得額外的美國專利，擴大了其酒精使用障礙候選藥物周圍的知識產權保護。
Photo via Shutterstock
圖片來自shutterstock。
譯文內容由第三人軟體翻譯。
